- IDEXX Laboratories has launched the Catalyst proBNP Test, the first dual-species in-clinic NT-proBNP cardiac assay for cats and dogs, extending its connected diagnostics portfolio and enabling real-time cardiac assessment on its nearly 80,000-strong Catalyst analyzer base.
- By opening access to an estimated US$4.00 billion global cardiac testing opportunity and embedding decision support into VetConnect PLUS, the new test could deepen IDEXX’s role in everyday veterinary cardiac care workflows.
- We’ll now examine how expanding in-clinic cardiac testing via the Catalyst proBNP Test may influence IDEXX’s broader investment narrative.
This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
IDEXX Laboratories Investment Narrative Recap
To own IDEXX, you generally need to believe its premium, recurring diagnostics model can keep compounding despite softer U.S. clinic visits and elevated competition. The Catalyst proBNP launch broadens IDEXX’s cardiac test menu and potentially supports near term consumables growth, but it does not fundamentally change the key swing factors today, which remain visit trends, instrument placement momentum, and the company’s ability to defend pricing as its valuation already embeds high expectations.
Among recent announcements, the expansion of SDMA into Catalyst CLIPs in May 2026 looks most directly connected to the proBNP launch, as both deepen the in clinic test menu on an existing installed base. Together, SDMA and proBNP point to a pattern of layering high value assays onto Catalyst, which could reinforce IDEXX’s recurring revenue story and help offset risks tied to slower U.S. visit growth and any future moderation in new instrument placements.
Yet against this attractive test expansion, investors should also be aware that sustained pressure on U.S. visit volumes could...
Read the full narrative on IDEXX Laboratories (it's free!)
IDEXX Laboratories' narrative projects $5.7 billion revenue and $1.5 billion earnings by 2029. This requires 8.7% yearly revenue growth and an earnings increase of about $0.4 billion from $1.1 billion today.
Uncover how IDEXX Laboratories' forecasts yield a $709.14 fair value, a 26% upside to its current price.
Exploring Other Perspectives
The most optimistic analysts were already assuming revenues reach about US$5.9 billion and earnings US$1.6 billion by 2029, so compared with consensus they are effectively betting that IDEXX’s recurring diagnostics flywheel, including advanced cardiac and cancer testing, proves much more powerful despite risks like rising cost conscious care models and regulatory uncertainty around proprietary platforms.
Explore 5 other fair value estimates on IDEXX Laboratories - why the stock might be worth as much as 43% more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your IDEXX Laboratories research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free IDEXX Laboratories research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEXX Laboratories' overall financial health at a glance.
Interested In Other Possibilities?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Uncover the next big thing with 21 elite penny stocks that balance risk and reward.
- Find 52 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com